FLVCR2 and acute myeloid leukemia: Gao et al. (2021) found that SLC2A3 was correlated with EMT and immune signature in colorectal cancer. Fan et al. (2022) verified that SLC25A38 was a novel biomarker for metastasis and clinical outcome in uveal melanoma. Our study focused on identifying FLVCR2 as a novel biomarker for AML, which may be an independent prognostic factor that influenced tumorigenesis and tumor immunology in AML progression. Despite our findings, this study has limitations. Hence, further investigations should analyze mechanisms related to FLVCR2-medicated tumor immunity and biological functions in vivo.